The global peripheral directional atherectomy system market size was estimated to be USD 0.684 billion in 2023 and is expected to reach at USD 1.29 billion by 2034 with a CAGR of 5.91% during the forecast period 2024-2034. Increasing technological advancements in atherectomy system procedures, rising usage of peripheral directional atherectomy systems, growing preference of minimally invasive endovascular procedures, surge in research & development activities, increasing launch of new products using peripheral directional atherectomy systems, and rising regulatory approvals atherectomy system are some of the key factors boosting the market growth.
Rising regulatory approvals atherectomy system is predicted to boost the market growth during the forecast period. As the initial therapy for Peripheral Artery Diseases (PAD), bypass surgery is no longer used as commonly as minimally invasive endovascular techniques to enlarge arterial opening, such as angioplasty or atherectomy. Real-time visualization of vessel shape and plaque characteristics is made possible by the combination of contemporary imaging technologies with PDAS systems. For instance, in June 2023, Avinger, Inc. has revealed that its advanced image-guided atherectomy system, Pantheris@ LV, designed to address Peripheral Artery Disease (PAD), has obtained FDA 510(k) clearance. The choice of equipment for atherectomy may vary depending on the nature of the blockage and the location of the lesion.
By product, directional atherectomy was the highest revenue-grossing segment in the global peripheral directional atherectomy system market in 2023 owing to growing adoption of minimally invasive atherectomy procedures, increasing research & development activities, and rising product launches. Additionally, Rotational atherectomy systems is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of cutting-edge technologies, surge in research & development activities, and increasing introduction of advanced systems. For instance, in October 2022, Cardiovascular Systems, Inc., a prominent medical device company specializing in the creation of advanced intervention systems for individuals suffering from peripheral and coronary artery disease, has introduced the 2.00 Max Crown, an innovative addition to their peripheral orbital atherectomy system. This new device is based on the well-established Diamondback 360 orbital atherectomy platform.
By end user, hospitals & surgical centers was the highest revenue-grossing segment in the global peripheral directional atherectomy system market in 2023 owing to rising demand for minimally invasive surgical procedures such as directional coronary atherectomy, increasing usage of atherectomy devices, growing approvals by regulatory bodies, and surge in mergers & acquisitions within market players. For instance, in February 2023, Abbott has made a formal commitment to acquire Cardiovascular Systems, Inc. (CSI), a medical device company known for its innovative atherectomy technology used in the treatment of peripheral and coronary artery disease. As part of this agreement, CSI shareholders will receive $20 per common share, with the total estimated equity value of the deal amounting to $890 million. Additionally, ambulatory care centers is predicted to grow at fastest CAGR during the forecast period owing increasing healthcare expenses, growing prevalence of chronic disorders, and rising minor procedures performed in ambulatory settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing investment for the development of cardiovascular products and growing product approvals by regulatory bodies. For instance, in August 2022, AngioDynamics, Inc., a forward-thinking medical technology firm committed to enhancing patients' quality of life, restoring proper blood circulation in the vascular system, and expanding cancer treatment possibilities, has declared that it has obtained FDA 510(k) clearance. This clearance has been granted for an extended use of the Auryon Atherectomy System, which now encompasses arterial thrombectomy. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising availability of reimbursements for atherectomy systems, increasing adoption of atherectomy systems, surge in number of clinical trials, growing approvals by regulatory bodies, and rising introduction of advanced systems. For instance, in April 2022, The Rotapro Rotational Atherectomy System, a recent introduction in India, represents cutting-edge technology. It employs a diamond-tipped burr that rotates steadily while cutting from the front to ensure a safe ablation process and streamline the intricate angioplasty procedure, ultimately enabling patients to be discharged within a 24-hour timeframe.
Rising regulatory approvals atherectomy system is predicted to boost the market growth during the forecast period. As the initial therapy for Peripheral Artery Diseases (PAD), bypass surgery is no longer used as commonly as minimally invasive endovascular techniques to enlarge arterial opening, such as angioplasty or atherectomy. Real-time visualization of vessel shape and plaque characteristics is made possible by the combination of contemporary imaging technologies with PDAS systems. For instance, in June 2023, Avinger, Inc. has revealed that its advanced image-guided atherectomy system, Pantheris@ LV, designed to address Peripheral Artery Disease (PAD), has obtained FDA 510(k) clearance. The choice of equipment for atherectomy may vary depending on the nature of the blockage and the location of the lesion.
By product, directional atherectomy was the highest revenue-grossing segment in the global peripheral directional atherectomy system market in 2023 owing to growing adoption of minimally invasive atherectomy procedures, increasing research & development activities, and rising product launches. Additionally, Rotational atherectomy systems is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of cutting-edge technologies, surge in research & development activities, and increasing introduction of advanced systems. For instance, in October 2022, Cardiovascular Systems, Inc., a prominent medical device company specializing in the creation of advanced intervention systems for individuals suffering from peripheral and coronary artery disease, has introduced the 2.00 Max Crown, an innovative addition to their peripheral orbital atherectomy system. This new device is based on the well-established Diamondback 360 orbital atherectomy platform.
By end user, hospitals & surgical centers was the highest revenue-grossing segment in the global peripheral directional atherectomy system market in 2023 owing to rising demand for minimally invasive surgical procedures such as directional coronary atherectomy, increasing usage of atherectomy devices, growing approvals by regulatory bodies, and surge in mergers & acquisitions within market players. For instance, in February 2023, Abbott has made a formal commitment to acquire Cardiovascular Systems, Inc. (CSI), a medical device company known for its innovative atherectomy technology used in the treatment of peripheral and coronary artery disease. As part of this agreement, CSI shareholders will receive $20 per common share, with the total estimated equity value of the deal amounting to $890 million. Additionally, ambulatory care centers is predicted to grow at fastest CAGR during the forecast period owing increasing healthcare expenses, growing prevalence of chronic disorders, and rising minor procedures performed in ambulatory settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing investment for the development of cardiovascular products and growing product approvals by regulatory bodies. For instance, in August 2022, AngioDynamics, Inc., a forward-thinking medical technology firm committed to enhancing patients' quality of life, restoring proper blood circulation in the vascular system, and expanding cancer treatment possibilities, has declared that it has obtained FDA 510(k) clearance. This clearance has been granted for an extended use of the Auryon Atherectomy System, which now encompasses arterial thrombectomy. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising availability of reimbursements for atherectomy systems, increasing adoption of atherectomy systems, surge in number of clinical trials, growing approvals by regulatory bodies, and rising introduction of advanced systems. For instance, in April 2022, The Rotapro Rotational Atherectomy System, a recent introduction in India, represents cutting-edge technology. It employs a diamond-tipped burr that rotates steadily while cutting from the front to ensure a safe ablation process and streamline the intricate angioplasty procedure, ultimately enabling patients to be discharged within a 24-hour timeframe.
Segmentation: Peripheral Directional Atherectomy System Market Report 2022 - 2033
Peripheral Directional Atherectomy System Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Rotational Atherectomy Systems
- Photo-ablative (Laser) Atherectomy Systems
- Orbital Atherectomy Systems
- Directional Atherectomy Systems
Peripheral Directional Atherectomy System Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Care Centers
- Hospitals & Surgical Centers
- Other
Peripheral Directional Atherectomy System Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Peripheral Directional Atherectomy System Market: Product Estimates & Trend Analysis
8. Peripheral Directional Atherectomy System Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Peripheral Directional Atherectomy System Market
11. Europe Global Peripheral Directional Atherectomy System Market
12. Asia Pacific Global Peripheral Directional Atherectomy System Market
13. Latin America Global Peripheral Directional Atherectomy System Market
14. MEA Global Peripheral Directional Atherectomy System Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Cardinal Health Inc.
- Koninklijke Philips NV
- B. Braun SE
- Boston Scientific Corporation
- Terumo Corporation
- Cardiovascular Systems Inc.
- Becton
- Dickinson and Company
- Medtronic
- AngioDynamics Inc.
- Abbott Laboratories
- RA Medical Systems
- Biomerics LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.68 Billion |
| Forecasted Market Value ( USD | $ 1.29 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
